Evidence map›Paper›PMID 41103360›Full record

ReviewInternational journal of nanomedicine2025

Advances in the Drug Delivery Systems for Psoriasis Topical Therapy.

Yang Liu, Ruizhen Chang, Huan Deng, Feiqing Liang, Xi Xu, Yuning Luo

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yang Liu *Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People's Republic of China.ORCID 0000-0003-0120-928X
Ruizhen Chang *Shenzhen Longgang Second People's Hospital, Shenzhen, Guangdong, 518112, People's Republic of China.
Huan DengShenzhen Longgang Second People's Hospital, Shenzhen, Guangdong, 518112, People's Republic of China.
Feiqing LiangShenzhen Longgang Second People's Hospital, Shenzhen, Guangdong, 518112, People's Republic of China.
Xi XuShenzhen Longgang Second People's Hospital, Shenzhen, Guangdong, 518112, People's Republic of China.
Yuning LuoShenzhen Longgang Second People's Hospital, Shenzhen, Guangdong, 518112, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis (PSO) is an immune-related skin disease featured by rapid and excessive cell growth leading to thick red scaly skin plaques. The main treatment strategy for PSO involves using anti-inflammatory drugs, immunosuppressants, etc, to relieve symptoms, suppress inflammation, and retard the overgrowth and division of skin cells. However, these drugs generally have disadvantages such as poor targeting, short half-life, low bioavailability, significant toxic side effects, etc. which impose a huge physiological and pathological burden on patients. Recently, the use of delivery systems to topical deliver drugs to the damaged psoriatic skin sites has received extensive attention from researchers. These systems promote drug stability, enhance drug penetration, and improve drug efficacies. The continuous development of various multifunctional topical delivery systems provides more therapeutic ideas for the cure of PSO. Based on this, this manuscript reviews the research progress of various delivery systems (including nanoparticles, hydrogels, microneedles, micelles, dendrimers, liposomes, nanoemulsions, vesicles, etc.) for PSO topical therapy and summarizes their development status in clinical treatment. It's expected to provide reference for the design of novel topical delivery systems and promote the development of PSO therapy methods.

Indexed as

Drug Delivery SystemsPsoriasisAdministration, CutaneousAdministration, TopicalAnimalsAnti-Inflammatory AgentsHumansHydrogelsLiposomesMicellesNanoparticlesSkinAnti-Inflammatory AgentsHydrogelsLiposomesMicellesdrug carrierdrug deliverypsoriasistopical therapy

Identifiers

PMID41103360
PMCPMC12526408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.